BioSpace News Archive

Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that the European Commission (EC) has granted marketing authorization for FINTEPLA® (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced receipt of U.S. Food and Drug Administration (FDA) permission for a Phase 1 study to proceed under the Company’s Investigational New Drug application (IND) for ON 123300, a proprietary, differentiated, first-in-class multi-kinase inhibitor. “We are grateful to receive this timely, favora

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, and City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, today announced that a Phase 1 single-center, two-arm cl

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that is has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI).

Recce Pharmaceuticals Ltd ( ASX: RCE ), the Company developing new classes of synthetic anti-infectives, is pleased to provide an update on its clinical programs. Topical Phase I/II Human Clinical Trial Submission Topical Phase I/II human clinical study is on track and progressing well. The Company recently announced it has received Human Research Ethics Approval for its Phase I/II human topical clinical trial in infected burn wounds an

Evotec SE and Alloy Therapeutics, a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, announced that the companies have entered into a technology partnership to expand Evotec’s antibody discovery platform.

Takeda continues to execute on global strategy focused on life-transforming treatments for patients living with complex and rare diseases

BioInvent International AB and Transgene announced they have received regulatory approval in Belgium for a clinical trial application for a Phase l/lla study of the novel oncolytic vaccinia virus BT-001.

Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a license agreement with Astrea Bioseparations for the use of the Affimer platform in affinity purification applications.

SIFI, a leading international eye care company, announces the launch of the WELL FUSION™ system and the Mini WELL PROXA® intraocular lens, offering a novel solution that provides cataract patients the option to treat presbyopia with spectacle-free uninterrupted high-quality vision at all distances and in all lighting conditions.